Black History Month - Being the Inspiration
Celebrate Black History Month with NBDF!  This year we will share stories from the Black community within the bleeding disorders community. These individuals are truly an inspiration to the entire inheritable blood and bleeding disorders…
National Bleeding Disorders Foundation Names Phil Gattone, M.Ed., Next Chief Executive Officer
For Immediate ReleaseCONTACT:Carrie L. StrehlauNational Bleeding Disorders Foundationcstrehlau@hemophilia.org901-230-4665National Bleeding Disorders Foundation Names Phil Gattone, M.Ed., Next Chief Executive Officer…
Novo Nordisk Experiencing Shortage of Rebinyn 3,000 IU Vials
Novo Nordisk recently informed NBDF that they are experiencing a temporary shortage of their product Rebinyn®, specifically in the 3,000 IU vial size. Rebinyn is a recombinant factor IX extended half-life therapy for the treatment of hemophilia B…
Wearable Neurostimulation to Promote Hemostasis in Bleeding Disorders
 *Note: Please click cc to activate the close captions for this video. Join us for a discussion on the science and mechanism around neurostimulation for hemostasis, and pre-clinical evidence for hemophilia A and B. The panel will also…
Setting the Health Equity, Diversity, and Inclusion Agenda for NBDF
By committing to health equity, diversity, and inclusion (HEDI) through a variety of efforts, NBDF strives to make a positive difference in the inheritable blood and bleeding disorders community’s equity and future. Join our HEDI team as they review…
FDA Approves Therapy for Rare Disorder Affecting Red Blood Cells
The U.S. Food and Drug Administration (FDA) has approved Fabhalta® (iptacopan), the first oral therapy for the treatment of adults with a rare blood disorder known as paroxysmal nocturnal hemoglobinuria (PNH). It is manufactured by Novartis. PNH…
Kathy Finkle
Philip M Gattone
Philip M. Gattone, M.Ed., is the president and chief executive officer of the National Bleeding Disorders Foundation (NBDF). He was named president in February 2024. Gattone is a seasoned leader dedicated to amplifying the impact of…
PARTNER EVENT: International Plasma Protein Congress
Plan to attend the 2024 International Plasma Protein Congress (IPPC) in Athens this April! The IPPC is an annual event organized by PPTA which covers topics including the need to increase plasma collection in Europe, regulatory and policy…
Government Relations Update - January 2024
Federal: Copay Accumulator Adjusters:  On Jan. 16, the Department of Health and Human Services withdrew its appeal of a U.S. District Court decision in September vacating the 2021 Notice of Benefit and Payment Parameters.…